anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
More than 60 monogenic genes mutated in steroid-resistant nephrotic syndrome (SRNS) have been identified. Our previous study found that mutations in nucleoporin 160 kD (NUP160) are implicated in SRNS. The NUP160 gene encodes a component of the nuclear pore complex. Recently, two siblings with homozygous NUP160 mutations presented with SRNS and a nervous system disorder. However, replication of nephrotic syndrome (NS)-associated phenotypes in a mammalian model following loss of Nup160 is needed to prove that NUP160 mutations cause SRNS. Here, we generated a podocyte-specific Nup160 knockout (Nup160podKO) mouse model using CRISPR/Cas9 and Cre/loxP technologies. We investigated NS-associated phenotypes in these Nup160podKO mice. We verified efficient abrogation of Nup160 in Nup160podKO mice at both the DNA and protein levels. We showed that Nup160podKO mice develop typical signs of NS. Nup160podKO mice exhibited progression of proteinuria to average albumin/creatinine ratio (ACR) levels of 15.06 ± 2.71 mg/mg at 26 weeks, and had lower serum albumin levels of 13.13 ± 1.34 g/l at 30 weeks. Littermate control mice had urinary ACR mean values of 0.03 mg/mg and serum albumin values of 22.89 ± 0.34 g/l at the corresponding ages. Further, Nup160podKO mice exhibited glomerulosclerosis compared with littermate control mice. Podocyte-specific Nup160 knockout in mice led to NS and glomerulosclerosis. Thus, our findings strongly support that mutations in NUP160 cause SRNS. The newly generated Nup160podKO mice are a reliable mammalian model for future study of the pathogenesis of NUP160-associated SRNS.
This phase I is designed to assess the safety and feasibility of a HLA-A\*02:01 restricted, HA-1H T cell receptor (TCR) transduced patient-derived T cell (MDG1021) immunotherapy, with secondary endpoints including preliminary efficacy, in patients with relapsed or persistent hematologic malignancies after allogeneic hematopoietic stem cell transplantation. In the dose-escalation part of the study, at least 9 patients will be treated with MDG1021 at 3 different doses to assess the safety and the maximum tolerated dose using a standard 3+3 cohort design. Thereafter, the selected optimal MDG1021 dose will be assessed for safety and preliminary efficacy in 20 additional patients during the dose-expansion part of the study. Manufacturing feasibility will be determined. MDG1021 will be administered by single intravenous infusion.

HA-1H is exclusively expressed on cells of the hematopoietic system. If the patient's blood-cells, and thus lymphoma or leukemic cells, carry the immunogenic version of the HA-1H antigen on their surface and the donor stem cells do not, MDG1021 immunotherapy could eradicate the patient's cancer cells and allow the donor stem cells to repopulate the patient's blood forming system.
<P>PROBLEM TO BE SOLVED: To provide a method for reducing pathological inflammation for a long period of time.  <P>SOLUTION: By administering a drug which specifically binds to α-4 integrin or a dimer including α-4 integrin, the pathological inflammation of a patient is reduced for a long period of time. Preferably, a monoclonal antibody or an immunologically active fragment thereof which binds to the dimer of α-4 integrin is used. Specifically, natalizumab is illustrated. The drug is effective for inflammation caused by multiple sclerosis, Crohn's disease, ulcerative colitis, inflammatory bowel disease or the like.  <P>COPYRIGHT: (C)2011,JPO&INPIT
PURPOSE:To produce a factor playing a part in differentiation of antibody- forming cell and to obtain a novel cell strain having autosynthesis ability, by cultivating a lymphoid cell of autoimmune disease animal together with a supernatant liquid obtained by cultivating a lymphoid cell of animal in the presence of a mitogen. CONSTITUTION:A lymphoid cell of an autoimmune disease animal (lymph node cell of MRL/l mouse) and a supernatant liquid prepared by cultivating a lymphoid cell of animal (lymph node of mesenterium) in the presence of mitogen are cultivated. The lymphoid cell is multiplied eight months from the starting of the cultivation without the supernatant liquid. A cell strain (KML1 cell, etc.,) having autosynthesis ability is established. This cell strain produces a factor (T cell replacing factor or BCDF) playing a part in differentiation of antibody-forming cell, but not a cell growth activity factor and is a null cell. A stable cell strain capable of being subjected to long-term subculture (subculture is possible when culture is restarted after the cell strain is lyophilized and melted) is obtained.
Active Treatment Arm: VITATOPS study tablet (folate 2 mg, B6 25 mg, B12 500 ug). Taken daily for the duration of the study.
The study is divided into a Core Phase, which includes the Double-Blind Treatment Period, and an Extension Phase in which all patients will be treated with fingolimod. The Core Phase is a 24-month, double-blind, randomized, active-controlled, parallel-group multicenter study phase to evaluate the efficacy and safety of fingolimod compared to IFN β-1a in children/adolescent patients aged 10-17 years old with MS. The Extension Phase is a 60-month (5 year) study phase for patients who complete the Core Phase of the study and meet all inclusion/exclusion criteria and for patients who will be recruited in the younger cohort to participate in the Extension Phase. The 'younger cohort' refers to the population of pediatric patients fulfilling any single one or a combination of the following criteria: being ≤12 years of age, or weighing ≤40 kg, or being prepubertal (i.e. pubertal status of Tanner stage \<2). The recruitment of the younger cohort (up to 25 patients) was requested as a post- approval health authority commitment
Group 3 will receive three vaccinations with the HIV DNA vaccine. Vaccinations will be given at study entry and Months 1 and 2. Participants will also receive an adenoviral vaccine boost subcutaneously at Month 6.
PROBLEM TO BE SOLVED: To obtain a hair dye composition comprising a specific pigment, a gelling agent and an oiling agent and excellent in usability. SOLUTION: This jelly-like temporary hair dye composition comprises one or more kinds of pigments having pearl gloss (e.g. titanium mica, carmine, azure or titanium mica coated with an azo pigment) in an amount of 5-40wt.% based on the whole composition, a gelling agent (e.g. a carboxyl vinyl polymer, an alkyl acrylate-acrylic acid copolymer) in an amount of 0.1-5wt.%, and an oily substance (e.g. castor oil or lanolin) in an amount of 0.5-20wt.%, and, if necessary, a film-forming polymer (e.g. a nonionic polymer compound, an amphoteric polymer compound) in an amount of 0.2-10wt.%. The composition is excellent in shieldability and abrasion resistance and free from tackiness and stiffness, and can uniformly dye hair.
Chronic exposure to loud sound leads to noise-induced hearing loss. This is especially common in collegiate-level musicians. Existing methods for estimating exposure typically do not consider genre- or instrument-specific variability in soundscape/spectral characteristics. We measured sound exposure levels (SELs) across instruments, bands, and genres at a university music school. We found (1) considerable variability in SELs across instruments and bands, (2) that Jazz musicians are consistently exposed to the highest sound levels, and (3) that spectral features of music differ between instrument type and genre, and based on room size. These findings highlight the need for tailored guidelines that moderate the implementation of hearing conservation initiatives for collegiate musicians.
The main aim of this study is to assess the efficiency of mouth-to-mouth ventilation through breathable self-sterilizing nanofiber respirators with accelerated copper in COVID-19 pandemic time. 100 volunteers (medical students trained as BLS trainers an medical students trained in BLS) will provide 2 minutes cycle of BLS according to European Resuscitation Council (ERC) guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper in three different mannequins: Professional Adult Medium Skin CPR-AED Training Manikin with CPR Monitor (Prestan), Resusci Anne QCPR AED (Laerdal), Resusci Baby QCPR (Laerdal). The mannequin will be utilised in a randomised order. The efficiency of mouth-to-mouth rescue breaths as "visible breath " and "not visible breath" will be recorded. In first BLS mannequin, the visibility of chest rising by the observer will be recorded. In two other mannequins, the ventilation metrics and each rescue breath evaluation in QCPR Skill Reporter will be recorded. Overall, 3 levels of visible breath according to the relation to set optimal breath volume (400 to 600 mL in adult, 30 to 50 mL in infant): low volume breath (below 400ml in adults and below 30ml in infant), optimal volume breath (between 400-600ml in adult and between 30-50 ml in infant), high volume breath (over 600ml in adult and over 50ml in infant) will be evaluated. For the primary analysis of efficiency of mouth-to-mouth ventilation, data from all three mannequins using outcome No breath / Visible breath will be evaluated. Secondary analysis will utilize data from two mannequins where detailed stratification No Breath / low / optimal / high Visible breath is possible. The mean volume of rescue breaths in the 2-minute cycle, average pause, longest pause, success in achieving the optimal breath volume, adverse events will be recorded. Regarding the technique of provided mouth-to-mouth ventilation, head tilt in adult or neutral position in infant and pinching of the nose will be evaluated.
CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients. Closely monitor growth (weight and height) in MAS-ER Capsule-treated pediatric patients treated with CNS stimulants.

In a controlled trial of MAS-ER Capsules in adolescents, mean weight change from baseline within the initial 4 weeks of therapy was –1.1 lbs. and –2.8 lbs., respectively, for patients receiving 10 and 20 mg MAS-ER Capsules. Higher doses were associated with greater weight loss within the initial 4 weeks of treatment. Chronic use of amphetamines can be expected to cause a similar suppression of growth [see Adverse Reactions (6.1)].

Pediatric patients who are not growing or gaining weight as expected may need to have their treatment interrupted.
BACKGROUND: The high utilization of acute care services, particularly emergency departments (ED), continues to be a significant concern for healthcare providers. Numerous approaches have been studied to meet the care needs of patients who frequently seek care in the ED; however, there is no comprehensive review of the current literature base. As such, a current understanding of the interventions initiated within the ED to address the needs of frequent users is required. This mapping review had three objectives: identify the characteristics associated with the need to frequently seek care in the ED; identify interventions implemented to address the needs of this population; and identify gaps in the current evidence base.
METHODS: A knowledge map was created by scoping the literature to identify characteristics associated with frequent ED use and interventions implemented to address frequent use. Then, a literature search was conducted to determine what has been implemented by EDs to reduce frequent ED use. The literature was searched from 2013 to January 2023. MeSH terms and keywords were used to identify relevant studies. Studies implementing an intervention for those with characteristics associated with frequent ED use and reporting on ED use were included.
RESULTS: Twenty-three (23) controlled trials and 35 observational studies were included. The most common populations were older adults, those with chronic conditions, and generic "frequent users". No studies assessed Indigenous Peoples or racial minorities, and few assessed patients with a disability or patients experiencing homelessness. The most common interventions were referrals, care plans, case management, care coordination, and follow-up phone calls. Most studies reported ED revisits, hospitalization, costs, length-of-stay, or outpatient utilization. Few assessed patient or staff perspectives. About one-third of studies (n = 24) reported significant reductions in ED revisits.
CONCLUSIONS: Similar interventions, mainly focused on care coordination and planning, have been implemented to address frequent use of the ED. There are still significant gaps in the populations that have been studied. Efforts now must be undertaken to study more diverse populations whose care needs are not being met elsewhere and thus frequent the ED often.
The current study examined whether meditation experience is associated with changes in endurance performance and inhibitory control-relevant neurocognitive functions caused by mental fatigue. Twenty-four athletes with meditation experience (AME) and twenty-five athletes without meditation experience (AWME) underwent a 30-min incongruent Stroop test in mental fatigue condition (MF) and a 30-min congruent Stroop test in control condition (CON) in a randomised-counterbalanced order. Inhibitory control-relevant neurocognitive functions were assessed using Flanker task and event-related potentials, followed by an endurance task using the Bruce treadmill protocol. Visual analogue scale was used to evaluate perceived mental fatigue (VAS-MF) before (T1), after Stroop test (T2) and after Flanker task (T3), and VAS for motivation (VAS-M) was used to evaluate motivation in Flanker task and endurance task. Results indicated that, compared to the CON, AWME in the MF exhibited overall lower accuracy, smaller incongruent N2 amplitude of the Flanker task (ps < .05), and shorter time to exhaustion (TTE) of the endurance task (p < .001), whereas AME did not exhibited difference in these outcomes between the conditions. Along with athletes in the MF reported lower VAS-M in endurance task. These findings suggest the benefits of meditation experience in mitigating the negative effects of mental fatigue.
Chronic-healing skin wounds are a common complication in diabetic individuals. To alleviate patient suffering, there is a pressing demand for more effective strategies to expedite the repair of diabetic wounds. Fibroblast growth factor 21(FGF21) has been proven to accelerate wound healing, but its stability and ability to assist in the healing of diabetic ulcers have not met expectations. Therefore, we have fused FGF21 with an elastin-like peptide (ELP) to create a recombinant fusion protein (abbreviated as "ELF") to increase the bioactivity and stability in vitro or in vivo. Our results demonstrated that ELF significantly improved the efficiency of FGF21 purification due to the inverse temperature responsive phase transition property of ELP. Meanwhile, the fusion strategy did not impair the structure of FGF21 or diminish its activity, as demonstrated by the highly similar secondary structure of ELF and FGF21, and their considerable inhibitory activity in the glucose consumption experiment of Huh-7 cells. An in vitro migration assay revealed that ELF promoted healing more effectively than either free FGF21 or ELP. Further in vivo study revealed the ability of ELF to improve skin wound healing quality, manifested by lower levels of inflammatory factors, more collagen formation and deposition, and the formation of robust vascular networks, though there was no significant difference in healing rate among the ELF, FGF21, and ELP groups. In conclusion, our study indicated that FGF21 and ELP fusion molecules could be developed as more efficient and cost-effective therapeutic strategies for diabetic wound healing.
Each participant will be asked to complete each standardised outcome measure (SOM) three times and each trial will be videotaped by the researcher. The selected SOM's are the 10 metre walk test, the timed up and go test, the functional reach test and the nine-hole peg test. A physiotherapist will watch the video on 2 separate occasions to evaluate intra-rater reliability. Inter-rater reliability will be assessed through asking three other neurofibromatosis specialist professionals (two NF1 consultants and one NF1 specialist nurse) to review the video and to score each measure completed. Once the filmed sessions have been analysed by the relevant clinician's the data will be destroyed in line with Trust policy.
The invention discloses a new application of Polyflavanostilbene A. Polyflavanostilbene A has an acetylcholinesterase inhibitory activity and a protective effect of nerve cells. As a multiple-target compound, Polyflavanostilbene A can be used in the preparation of a medicine for resisting Alzheimer disease. The application of Polyflavanostilbene A in the preparation of a medicine for treating Alzheimer disease is disclosed for the first time. As the matrix type belongs to a brand new matrix type, and the inhibitory activity of acetylcholinesterase is unexpectedly strong. There is no possibility for any revelation of other compounds. Polyflavanostilbene A has protrude substantive features, and is a remarkable progress for preventing and treating Alzheimer disease.
Eligible patients who are enrolled in the study will receive standard surgical stabilization within 72 hours of injury. All Subjects will receive the Twin Star ECSPRESS catheters, which will be inserted at the end of the surgical procedure to stabilize the tibia fracture and will be connected to the pressure monitor in the operating room or immediately upon arrival in the recovery room. The catheters will be used for up to 24-hours after surgical fixation of the affected lower leg in order to (1) measure and record muscle compartment pressure, and (2) remove interstitial fluid in the subset of subjects that are randomized to the Treatment Group. Subjects will be followed closely during the 24 hours the catheter is inserted to gather muscle pressure data, occurrance of a fasciotomy, adverse events, etc. and then followed up at 2 weeks, 3 months, 6 months and 12 months post study enrollment after which the subjects participation in the study will be completed. There will no interim data analysis of the study outcomes during the conduct of this study. Data analysis and presentation of the data will be made after study closure.
The prevalence of cerebral palsy is increasing as the survival rate of extremely premature infants is improving. Studies have suggested an apparent association between maternal magnesium sulfate administration and a reduced risk of cerebral palsy. Other studies have suggested a possible association between magnesium sulfate and a reduction in neonatal cranial ultrasound abnormalities which may be markers for subsequent development of cerebral palsy.

This multicenter trial tests whether prophylactic magnesium sulfate given to women, for whom preterm delivery is imminent, reduces the risk of death or moderate to severe cerebral palsy in their children. Women presenting from 24.0 to 31.6 weeks gestation with advanced preterm labor or premature rupture of the membranes (pPROM) and no recent exposure to magnesium sulfate are randomized to receive either intravenous magnesium sulfate or masked study drug placebo. The study drug is administered as a 6 gram loading dose followed by a 2 gram/hour infusion (or equivalent rate for placebo). If after 12 hours, delivery has not occurred and is not anticipated, the infusion is stopped. No other parenteral tocolytics other than the IV medication may be used. Retreatment with study medication is given any time labor recurs or delivery is anticipated until gestational age is \> 34.0 wks. Standard clinical management and therapy is to be maintained for all study patients. Patients are assessed for signs of intolerance to the study medications and maternal data are collected up to hospital discharge. A sample of venous blood is collected and neonatal cranial ultrasounds are performed. Up to three follow-up visits are scheduled over two years where certified examiners, masked to study group assignment, collect physical and neurological data, including a modified Gross Motor Function Classification Scale. The Bayley Scales of Infant Development is also administered. Cranial ultrasounds are reviewed centrally.

The primary outcome is a composite outcome of death or moderate to severe cerebral palsy. Secondary outcomes include maternal infectious morbidity, pulmonary edema and placental abruption, neonatal stillbirth and death, intraventricular hemorrhage, periventricular leukomalacia, neonatal infectious and noninfectious morbidity.
A pharmaceutical composition containing obovatol and its derivatives is provided to enhance the activity of AMPK(AMP-activated protein kinase) which acts pivotal role in diabetes and metabolic diseases and treat diabetes and metabolic diseases. A pharmaceutical composition for preventing or treating diabetes comprises an obovatol of chemical formula 1 and its derivative as an active ingredient. In the chemical formula 1, R1 and R2 is hydrogen, straight or branched alkyl of C1-C7, acetyl or alkoxyacetyl of C1-C7; R3 is hydrogen, straight or branched alkyl of C1-C7, alkenyl of C2-C7 or aryl. R1 and R2 is independently or selectively methyl, ethyl, acetyl, methoxy, ethoxy, methoxyacetyl or ethoxyacetyl; and R3 is hydrogen, propyl, prophenyl or arlyl. The pharmaceutical composition further comprises a pharmaceutically allowable carrier, excipient, and diluents. The composition is used in a form of powder, granule, tablet, capsule, suspension, emulsion, syrup, oral formulation of aerosol, suppository or sterilization injection solution.
The present invention provides an antibody to human IL-3R.alpha. chain, which does not inhibit IL-3 signaling and binds to B domain of the human IL-3R.alpha. chain but does not bind to C domain of the human IL-3R.alpha. chain. Also provided is a composition comprising the IL-3R.alpha. antibody and a pharmaceutically acceptable carrier. Uses of the IL-3R.alpha. antibody and the composition for preventing or treating leukemia in a subject are also provided, in which a cell expressing IL-3R.alpha. is found in bone marrow or peripheral blood of a subject. Also provided is a composition for detecting leukemia, comprising the IL-3R.alpha. antibody and a pharmaceutically acceptable carrier, in which a cell expressing IL-3R.alpha. is found in bone marrow or peripheral blood of a biological sample from a subject.
The invention relates to the field of dermatology and cosmetology and can be used for cosmetically treating the skin using cold plasma. The present method includes cleaning the skin, applying analgesics to a skin surface, and treating the skin surface with a source of cold plasma moved translationally along a linear path, with the use of a serum. Next, an area of skin to which serum is applied is retreated with the source of cold plasma, which is moved translationally along linear paths. The skin surface is then treated with an alcohol-free antiseptic, and a cosmetic mask impregnated into a fabric is applied. The cosmetic mask contains royal jelly, vitamin E, coenzyme Q10, lidocaine, plant ingredients in the form of extracts of aloe, ginseng, calendula, linden, chamomile, sage, yarrow, watermelon seeds and Siberian fir, and substances that have a regenerative effect. Using the invention makes it possible to compensate for age-related changes to the skin, while also enhancing the treatment effect through the use of a cosmetic mask and rendering the procedure effective for a longer period without irritating damaged areas of skin.
Participants randomized into this group will be receiving the standard medical care and "placebo" acupuncture. For the placebo acupuncture procedure, the ASP® needles will be double taped onto the ear in the same anatomical position as the acupuncture groups. The needles will be taped so that the needles will never puncture the skin. The patients will then be given hydrocodone / acetaminophen 5mg/325mg (generic) with a prescription to take home and use as needed.